Taxifolin Attenuates Hepatic Fibrosis and Injury in High-Fat Diet and Streptozotocin-Induced Type 2 Diabetes Mice
Main Article Content
Abstract
This study investigated the protective effects of taxifolin (TAX), a bioflavonoid, against hepatic fibrosis and injury in the type 2 diabetes mellitus (T2DM) mouse model. T2DM model was induced in male C57BL/6 mice by high-fat diet (HFD) and intraperitoneal injection for 5 consecutive days of 40 mg/kg streptozotocin (STZ). HFD-STZ groups were administered TAX (80 mg/kg/day) or vehicle daily for 12 weeks. The control or wild-type (WT) group received equal amounts of the vehicle and was fed a normal chow diet. Body weight and blood glucose were checked every 4 weeks. H&E and Masson's trichrome staining were performed to assess liver fibrosis and injury. The western blot was used to determine the expression levels of key fibrotic proteins. The data showed that taxifolin treatment significantly decreased body weight, liver weight, and blood glucose in diabetic mice. In particular, liver enzymes including alanine transaminase (ALT) and aspartate transferase (AST), and triglyceride levels were significantly higher in the non-treated diabetic group than in the WT group but markedly reduced after TAX treatment. In addition, the histological analysis revealed that TAX attenuated hepatic interstitial fibrosis. Moreover, western blot data showed downregulation of fibrotic markers including TGF-β1, Col1a1, and Smad2 in TAX group treatment indicating the molecular mechanisms through which TAX exerts its hepatoprotective effects. These findings suggest that TAX holds therapeutic potential in mitigating liver fibrosis and injury associated with T2DM, providing a promising avenue for further research and potential clinical application.
References
[2] U. G. Garcia, A. B. Vicente, S. Jebari, A. L. Sebal, H. Siddiqi, K. B. Uribe et al., Pathophysiology of Type 2 Diabetes Mellitus, Int. J. Mol. Sci, Vol. 21, No. 17, 2020, https://doi.org/10.3390/ijms21176275.
[3] D. Ferguson, B. N. Finck, Emerging Therapeutic Approaches for the Treatment of NAFLD and Type 2 Diabetes Mellitus, Nat. Rev. Endocrinol, Vol. 17, No. 8, 2021, pp. 484-95, https://doi.org/10.1038/s41574-021-00507-z.
[4] C. H. Lee, D. T. Lui, K. S. Lam, Non-alcoholic Fatty Liver Disease and Type 2 Diabetes: An Update, J. Diabetes Investig, Vol. 13, No. 6, 2022, pp. 930-40, https://doi.org/10.1111/jdi.13756.
[5] P. Rada, A. G. Rodríguez, C. G. Monzón, A. M. Valverde, Understanding Lipotoxicity in NAFLD Pathogenesis: is CD36 a Key Driver? Cell Death Dis, Vol. 11, No. 9, 2020, pp. 802, https://doi.org/10.1038/s41419-020-03003-w.
[6] A. Mantovani, E. Scorletti, A. Mosca, A. Alisi, C. D. Byrne, G. Targher, Complications, Morbidity and Mortality of Nonalcoholic Fatty Liver Disease, Metabolism, Vol. 111, 2020, pp. 154170, https://doi.org/10.1016/j.metabol.2020.154170.
[7] V. G. Athyros, S. A. Polyzos, J. Kountouras, N. Katsiki, P. Anagnostis, M. Doumas et al., Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus, New Kids on the Block, Curr. Vasc. Pharmacol, Vol. 18, No. 2, 2020, pp. 172-81, https://doi.org/10.2174/1570161117666190405164313.
[8] B. C. Simes, G. G. MacGregor, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide, Diabetes Metab. Syndr. Obes, Vol. 12, 2019, pp. 2125-36, https://doi.org/10.2147/DMSO.S212003.
[9] Y. Liu, X. Shi, Y. Tian, S. Zhai, Y. Liu, Z. Xiong et al., An Insight into Novel Therapeutic Potentials of Taxifolin, Front. Pharmacol, Vol. 14, 2023, pp. 1173855, https://doi.org/10.3389/fphar.2023.1173855.
[10] V. S. Shubina, Y. V. Shatalin, Antioxidant and Iron-chelating Properties of Taxifolin and its Condensation Product with Glyoxylic Acid, J. Food Sci. Technol, Vol. 54, No. 6, 2017, pp. 1467-75, https://doi.org/10.1007/s13197-017-2573-0.
[11] S. Saito, Y. Yamamoto, T. Maki, Y. Hattori, H. Ito, K. Mizuno et al., Taxifolin Inhibits Amyloid-β Oligomer Formation and Fully Restores Vascular Integrity and Memory in Cerebral Amyloid Angiopathy, Acta Neuropathologica Communications, Vol. 5, No. 1, 2017, pp. 26,
https://doi.org/10.1186/s40478-017-0429-5.
[12] C. L. Yang, Y. S. Lin, K. F. Liu, W. H. Peng,
C. M. Hsu, Hepatoprotective Mechanisms of Taxifolin on Carbon Tetrachloride-Induced Acute Liver Injury in Mice, Nutrients, Vol. 11, No. 11, 2019, https://doi.org/10.3390/nu11112655.
[13] Z. Y. Zhan, M. Wu, Y. Shang, M. Jiang, J. Liu, C. Y. Qiao et al., Taxifolin Ameliorate High-fat-diet Feeding Plus Acute Ethanol Binge-induced Steatohepatitis through Inhibiting Inflammatory Caspase-1-dependent Pyroptosis, Food Funct, Vol. 12, No. 1, 2021, pp. 362-72, https://doi.org/10.1039/d0fo02653k.
[14] D. E. Kleiner, E. M. Brunt, M. V. Natta, C. Behling, M. J. Contos, O. W. Cummings et al., Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease, Hepatology, Vol. 41, No. 6, 2005, pp. 1313-21, https://doi.org/10.1002/hep.20701.
[15] W. Liang, A. L. Menke, A. Driessen, G. H. Koek, J. H. Lindeman, R. Stoop et al., Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology, PLoS one, Vol. 9, No. 12, 2014, pp. e115922, https://doi.org/10.1371/journal.pone.0115922.
[16] T. Inoue, B. Fu, M. Nishio, M. Tanaka, H. Kato, M. Tanaka et al., Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis, Nutrients, Vol. 15, No. 2, 2023,
https://doi.org/10.3390/nu15020350.
[17] H. Jaeschke, G. J. Gores, A. I. Cederbaum, J. A. Hinson, D. Pessayre, J. J. Lemasters, Mechanisms of Hepatotoxicity, Toxicol. Sci, Vol. 65, No. 2, 2002, pp. 166-76, https://doi.org/10.1093/toxsci/65.2.166.
[18] M. Parola, M. Pinzani, Liver Fibrosis in NAFLD/NASH: from Pathophysiology Towards Diagnostic and Therapeutic Strategies, Mol. Aspects Med, Vol. 95, 2024, pp. 101231, https://doi.org/10.1016/j.mam.2023.101231.
[19] L. J. M. Heyens, D. Busschots, G. H. Koek, G. Robaeys, S. Francque, Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front. Med, Vol. 8,
No. 615978, 2021, https://doi.org/10.3389/fmed.2021.615978.
[20] I. Fabregat, J. M. Càceres, A. Sánchez, S. Dooley, B. Dewidar, G. Giannelli et al., TGF-β Signalling and Liver Disease, Febs J, Vol. 283, No. 12, 2016, pp. 2219-32, https://doi.org/10.1111/febs.13665.
[21] F. Xu, C. Liu, D. Zhou, L. Zhang, TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis, J. Histochem. Cytochem, Vol. 64, No. 3, 2016, pp. 157-67, https://doi.org/10.1369/0022155415627681.